Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT chemoradiotherapy with capecitabine and post-radiation chemotherapy for lower rectal cancer
IRCT20150929024266N6Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in rectal cancer, sponsored by Tehran University of Medical Sciences. Primary endpoints: Complete clinical response rate, Tumor regression rate and 1 more. Started Jan 2024; status: completed.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on IRCT20150929024266N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150929024266N6.